A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leukemia

A Phase I Study of a Bcr-abl peptide based Vaccine with GM-CSF as an Adjuvant in Patients with Chronic Myleogenous Leukemia

Alexander Gaiger (ORCID: 0000-0001-6340-3446)

Disciplines

Health Sciences (30%); Clinical Medicine (50%); Medical-Theoretical Sciences, Pharmacy (20%)

Keywords

    LEUKÄMIE, IMMUNTHERAPIE, VACCINE, BCR-ABL

Research institution(s)